dc.contributor.author | Tsantes, Argirio E. | en |
dc.contributor.author | Nikolopoulos, Georgios K. | en |
dc.contributor.author | Bagos, Pantelis G. | en |
dc.contributor.author | Bonovas, Stefanos | en |
dc.contributor.author | Kopterides, Petros | en |
dc.contributor.author | Vaiopoulos, G. | en |
dc.creator | Tsantes, Argirio E. | en |
dc.creator | Nikolopoulos, Georgios K. | en |
dc.creator | Bagos, Pantelis G. | en |
dc.creator | Bonovas, Stefanos | en |
dc.creator | Kopterides, Petros | en |
dc.creator | Vaiopoulos, G. | en |
dc.date.accessioned | 2018-06-22T09:53:24Z | |
dc.date.available | 2018-06-22T09:53:24Z | |
dc.date.issued | 2008 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41815 | |
dc.description.abstract | Plasminogen activator inhibitor (PAI-1), is the central component of the fibrinolytic system. A deletion/insertion (4G/5G) polymorphism in the promoter region of the PAI-1 gene has been correlated with levels of plasma PAI-1. The 4G allele is associated with higher levels of PAI-1, and might increase the risk for intravascular thrombosis. However, the contribution of this genetic variant to the risk for thrombosis, both arterial and venous, has not been clearly established. A broad spectrum of findings regarding the effect of the 4G allele on thrombotic risk in different target organs has been reported. Our aim is to summarize the variable influence of this polymorphism on thrombotic events in different tissues or organs and explain the underlying mechanisms accounting for these differences. © 2007 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Thrombosis research | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Thrombosis | en |
dc.subject | Review | en |
dc.subject | Allele | en |
dc.subject | Genetic susceptibility | en |
dc.subject | Genotype | en |
dc.subject | Heart infarction | en |
dc.subject | Polymorphism | en |
dc.subject | Genetic | en |
dc.subject | Promoter region | en |
dc.subject | Protein expression | en |
dc.subject | Cardiovascular risk | en |
dc.subject | Disease severity | en |
dc.subject | Artery thrombosis | en |
dc.subject | 4g/5g polymorphism | en |
dc.subject | Plasminogen activator inhibitor 1 | en |
dc.subject | Genetic variability | en |
dc.subject | Cerebrovascular accident | en |
dc.subject | Brain ischemia | en |
dc.subject | Pai-1 | en |
dc.subject | Protein polymorphism | en |
dc.subject | Stroke | en |
dc.subject | Thrombotic risk | en |
dc.subject | Vein thrombosis | en |
dc.subject | Venous thromboembolism | en |
dc.title | The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.thromres.2007.09.005 | |
dc.description.volume | 122 | |
dc.description.issue | 6 | |
dc.description.startingpage | 736 | |
dc.description.endingpage | 742 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Nikolopoulos, Georgios K.[0000-0002-3307-0246] | |
dc.contributor.orcid | Bagos, Pantelis G. [0000-0003-4935-2325] | |
dc.contributor.orcid | Bonovas, Stefanos [0000-0001-6102-6579] | |
dc.contributor.orcid | Kopterides, Petros [0000-0002-7682-4482] | |
dc.gnosis.orcid | 0000-0002-3307-0246 | |
dc.gnosis.orcid | 0000-0003-4935-2325 | |
dc.gnosis.orcid | 0000-0001-6102-6579 | |
dc.gnosis.orcid | 0000-0002-7682-4482 | |